Noile-Immune Biotech (TSE:4893) Research & Development: 円159.74 Mil (TTM As of Dec. 2025)


TSE:4893 Noile-Immune Biotech Inc TSE:4893
54 GF Score
Price 円120.00
GF Value 円4.38
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Noile-Immune Biotech Research & Development?

Noile-Immune Biotech TSE:4893 +0.84% 54 Research & Development is 円159.74 Mil as of Dec. 2025. GuruFocus rates TSE:4893 with a GF Score™ of 54/100 and a GF Value™ of 円4.38 (Significantly Overvalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Noile-Immune Biotech's Research & Development for the three months ended in Dec. 2025 was 円0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was 円159.74 Mil.

Noile-Immune Biotech  (TSE:4893) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Noile-Immune Biotech Research & Development Related Terms

Noile-Immune Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Noile-Immune Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech Research & Development Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 514.83 334.80 646.71 579.88 360.88

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 122.37 73.59 0.00 86.16
TSE:4893
54GF Score
Noile-Immune Biotech Inc TSE:4893
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Noile-Immune Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円159.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of 円159.74 Mil mean?
Noile-Immune Biotech (TSE:4893) has a Research & Development of 円159.74 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Noile-Immune Biotech and its competitors.
Is Noile-Immune Biotech's Research & Development too high?
Noile-Immune Biotech's current Research & Development is 円159.74 Mil. Overall, Noile-Immune Biotech has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Noile-Immune Biotech's Research & Development compare to VRTX and REGN?
Noile-Immune Biotech's Research & Development of 円159.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Noile-Immune Biotech and its competitors. Noile-Immune Biotech's current Research & Development is 円159.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Noile-Immune Biotech stock overvalued right now?
Based on GuruFocus' analysis, Noile-Immune Biotech (TSE:4893) is currently considered Significantly Overvalued. The stock's GF Value™ is 円4.38, compared to a current price of 円120.00 — trading 2639.7% above its estimated fair value. The current Research & Development is 円159.74 Mil. Noile-Immune Biotech's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Noile-Immune Biotech (TSE:4893), the current Research & Development is 円159.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Noile-Immune Biotech (TSE:4893) Overvalued in 2026?

Based on GuruFocus' analysis, Noile-Immune Biotech stock appears to be overvalued. The current stock price of 円120.00 is trading 2639.7% above its estimated GF Value™ of 円4.38. GuruFocus considers Noile-Immune Biotech to be Significantly Overvalued.

Key valuation signals for TSE:4893:

  • Research & Development: 円159.74 Mil
  • GF Value™: 円4.38 vs. price of 円120.00 (2639.7% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the TSE:4893 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Noile-Immune Biotech Business Description

Address 2-12-10 Shiba-Daimon, 5th Floor, T&G Hamamatsucho Building, Minato-ku, Yamaguchi, Tokyo, JPN, 105-0012
Noile-Immune Biotech Inc is engaged in the development of CAR-T cell therapy for solid cancers using its proprietary technology. The company's development pipeline and collaborative projects with other companies include different product candidates such as NIB102, NIB103, NIB104, ADAP01, AUTL01, etc. It operates in a single segment, the cancer immunotherapy drug discovery business.
54GF Score

Get the complete analysis for TSE:4893

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円120.00
Price
円4.38
GF Value